Poliquimioterapia secuencial (carboplatino/vp-16) versus alternante (carboplatino/vp-16 y ciclofosfamida/vincristina/adriamicina) en el carcinoma microcítico de pulmón

Sánchez de Cos Escuín, J.; Masa Jiménez, F.; de la Cruz Ríos, J.L.; Martínez Verdasco, A.

doi:10.1016/S0300-2896(15)31572-6

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

Archivos de Bronconeumologia has received the new Impact Factor (JCR). The impact factor has risen from 6.333 in 2021 to 8 in the last evaluated year, 2022.
It is needed to be a member of SEPAR or have a subscription to access full texts of articles published last year. Abstracts are available for all visitors.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2022

Citescore

CiteScore measures average citations received per document published.

Citescore 2022

2.8

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2022

0.434

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2022

0.437

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 26. Issue 7.

Pages 292-296 (October 1990)

More article options

Pages 292-296 (October 1990)

DOI: 10.1016/S0300-2896(15)31572-6

Full text access

Poliquimioterapia secuencial (carboplatino/vp-16) versus alternante (carboplatino/vp-16 y ciclofosfamida/vincristina/adriamicina) en el carcinoma microcítico de pulmón

Sequential polychemotherapy (carboplatinum/VP-16) vs alternating (carboplatinum/VP-16) and cyclophosphamide/vincristine/adriamicine in the treatment of microcytic carcinoma of the lung

Visits

3781

Download PDF

J. Sánchez de Cos Escuín, F. Masa Jiménez, J.L. de la Cruz Ríos, A. Martínez Verdasco

Unidad de Neumología. Servicio de Medicina Interna. Hospital de la S.S. San Pedro de Alcantara. Cáceres

This item has received

3781 Visits

Article information

Abstract

Bibliography

Download PDF

Statistics

Se analizan los resultados obtenidos en el tratamiento del carcinoma microcítico de pulmón mediante 2 pautas de poliquimioterapia: A (secuencial: 6 ciclos de carboplatino y VP16, intervalados cada 21 días) y B (alternante: ciclos 1, 3 y 5 iguales al anterior y ciclos 2, 4 y 6 con ciclofosfamida, vincristina y adriamicina). Resultaron evaluables 37 pacientes: 24 de la pauta A y 13 de la B. Se obtuvo un 100% de respuestas globales (40% de respuestas completas [RC] y 60% de parciales [RP]) en casos de enfermedad limitada con ambos regímenes. En casos de enfermedad extendida, hubo un 78,5% de respuestas globales con la pauta A (21,4% RC y 57,1% RP) y 87,5% con la B (25% RC, y 62,5% RP). Aunque las tasas de respuesta fueron similares, la pauta B fue mejor tolerada, permitiendo un mayor grado de cumplimiento de la dosis (diferencia estadística casi significativa: p < 0,1). Sólo hubo un fallecimiento debido a citostáticos (pauta A) y los efectos tóxicos graves fueron escasos en ambos grupos.

We analyze the results obtained in the treatment of the microcytic carcinoma of the lung using two types of polychemotherapy: A (sequential: 6 cycles of carboplatinum and VP-16 with 21 days interval between them) and B: (alternating: cycles number 1,3, and S identical to the previous schedule and cycles number 2,4, and 6 with cyclophosphamide, vincristine and adriamicine). We included for the analysis 37 patients: 24 with A model and 13 with type B. In cases of limited disease we obtained a 100% of responses (40% of complete response (CR) and 60% of partial result (PR)) using both regimes. In cases of disseminated illness we observed 78.5 of global responses with model A (21.4% CR and 57.1 PR) and 87.5 with type B (25% CR and 62.5% PR). The regime B was more well tolerated than model A and although the rates of response were comparable, patients treated with model B had a higher degree of fulfilment of the doses (differences nearly significant: p< 0.1). We observed a death dne to the cytostatic treatment in schedule A. The toxic effects were scanty in both groups of patients.

Full text is only aviable in PDF

Bibliografía

[1.]

J. García Conde, V. Alberola, A. Lluch.

Avances en el tratamiento del carcinoma microcítico de pulmón.

En: Avances en Medicina Interna, (1988), pp. 79-88

[2.]

A. Ordóñez Gallego, C. García Girón, J. Feliu Batlle.

Estado actual en el tratamiento del carcinoma broncopulmonar de células pequeñas.

Arch Bronconeumol, 24 (1988), pp. 15-20

[3.]

B.E. Johnson, J.D. Minnu.

Small cell lung cancer.

En: Pulmonary diseases and disorders. Fishman AP, 2a 3d. Mc Graw-Hill, (1988), pp. 1971-1981

[4.]

C. Boni, G. Cocconi, G. Buragui, et al.

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer.

Cancer, 63 (1989), pp. 638-642

Medline

[5.]

J. Vicente, G. Martín, J. Feliu, et al.

Carcinoma microcítico de pulmón.

Quimioterapia alternante más radioterapia. Regímenes A/ifosfamida, vincristina B/carboplatino, ciclofosfamida, VP-16. Resultados preliminares. II Congreso Nacional de Oncología Médica, (1989),

[6.]

P.I. Clark, M.L. Slevin.

Small cell lung cancer: Single agents revisted.

Respir Med, 83 (1989), pp. 381-382

Medline

[7.]

S.G. Spiro.

La quimioterapia en el cáncer pulmonar de células pequeñas.

Br Med J (ed esp), 1 (1986), pp. 17-20

[8.]

J. Sánchez de Cos, J. Redondo, A. Sever, A. García, J. De la Cruz, F. Masa.

Carcinoma broncopulmonar.

Estudio epidemiológico clínico de 157 casos. Atención Primaria, 6 (1989), pp. 304-311

[9.]

V.S. Prasad, A.R. Naylor, W.S. Walker, D. Lamb, E.W. Cameron, P.R. Walbaum.

Long term survival after pulmonary resection for small cell carcinoma of the lung.

Thorax, 44 (1989), pp. 784-787

Medline

[10.]

K. Karrer, H. Denck, P. Drings, J. Orel, M.F. Bruno.

Cooperative Group. Combination of surgery and chemotherapy for small-cell bronchial carcinoma.

Drugs Exp Res, 12 (1986), pp. 191-200

[11.]

P.A. Bunn, A.S. Lichter, R.W. Makich, et al.

Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer.

Ann Intern Med, 106 (1987), pp. 655-662

Medline

[12.]

M.L. Perry, W.L. Baton, K.J. Propert, et al.

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

N Engl J Med, 316 (1987), pp. 912-918

http://dx.doi.org/10.1056/NEJM198704093161504 | Medline

[13.]

E. Nou, O. Brodin, J. Bergh.

A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens.

Cancer, 62 (1988), pp. 1079-1090

Medline

[14.]

W.K. Evans, R. Feld, N. Murray, et al.

The use of VP-16 plus cisplatin during induction chemotherapy for small cell lung cancer.

Semin Oncol, 13 (1986), pp. 10-16

Medline

[15.]

L.H. Einhorn, J. Crawford, R. Birch, G. Omura, J. Johnson, F.A. Greco.

Cisplatin plus etoposide consolidation following cyclophosphamide doxorrubicin and vincristine in limited small cell lung cancer.

Jour Clin Oncol, 6 (1988), pp. 451-456

[16.]

I.G. Smith, T.J. Perren, M.J. Plant, et al.

Carboplatin.

VP-16 and ifosfamide, intensive chemotherapy for small cell lung carcinoma. Proc ECCO, 4 (1987), pp. 6

[17.]

M.J. Lindt, H. Anderson, D.B. Smitdh, et al.

Carboplatin, ifosfamide, etoposide with mid course vincristine and thoracic radiotherapy for limited stage small cell lung cancer.

Proc ECCO, 4 (1987), pp. 7

[18.]

V. Gatzeemeier, W. Achterath, M. Keckmayr, et al.

Pilot study with carboplatin/vincristine/etoposide as first line therapy in extensive small cell lung cancer.

Proc ECCO, 4 (1987), pp. 17

[19.]

J.M. Gracia, A. Querejeta, E. Esteban, et al.

Alternating scheme of chemotherapy with carboplatin (CBDCA) VP-16, ifosfamide, doxorrubicin and vincristine plus radiotherapy in the treatment of small cell lung cancer.

Preliminary results. Proc ECCO, 4 (1987), pp. 7

[20.]

Clemente MG, Muñiz MM, Escudero C, Molinos L, Ramos S, Martínez J. Carboplatino y etopósido asociados a radioterapia torácica como tratamiento primario del carcinoma broncogénico de célula pequeña (CBCP): experiencia en 47 casos tratados en una unidad de Neumología.

[21.]

M.B. Mc Illmurray, R.J. Bibby, B.E. Taylor, et al.

Etoposide compareed with the combination of vincristine, doxorrubicin and cyclpohosphamide in the treatment of small cell lung cancer.

Thorax, 44 (1989), pp. 215-219

Medline

[22.]

I.E. Smith, B.D. Evans, M.E. Gore, et al.

Carboplatin and etoposide as first line combination therapy for small cell lung cancer.

J Clin Oncol, 5 (1987), pp. 185-189

http://dx.doi.org/10.1200/jco.1987.5.2.185 | Medline

[23.]

J.R. Daniels, L.Y. Chak, B.I. Siric, et al.